This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $346,319.00 to the University of Pittsburgh to conduct research on "INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER." The award period runs from August 1, 2024 to July 31, 2027. The University of Pittsburgh, a major public research university, will leverage its expertise in biomedical sciences, cancer biology, and immunology to investigate genomic markers that could predict the efficacy of immunotherapy for patients with triple-negative breast cancer. This research aims to advance medical understanding and treatment of this challenging form of breast cancer, which disproportionately impacts military service members and veterans.